Thompson_97--congrats on your huge Apple gains--well done--good to see you posting--appreciate your input--also very long Apple (since '08)--not planning on selling anytime soon !!!!!
berchik--I have to agree---3 months ago ~early Jan. Apple did a triple bottom in the 106 area and then rallied into and thru earnings to the 133 area. We are now bottoming here around 123ish getting set to rally before and thru earnings how high did you say ?? 145-150?--best of luck Apple longs !!!! The pattern repeats !!
The rest of the recommendation from Canaccord.....Newman wrote, “We expect data in solid tumors by 2H15 at a major medical conference, a key catalyst for the stock. We expect positive data due to the fact that IDH1 mutations demonstrate a homogenous expression of R132 allele in solid tumors, which have been shown to be a positive prognostic factor (~1 year in glioblastoma) for survival. Importantly, investors may have expected AG-120 solid tumor data earlier, but solid tumor patients are evaluated at more distinct time points vs. hematological malignancies, where the time point for evaluation of hematologic malignancies is more flexible. Interestingly, AGIO noted that preclinical data in hematological and solid tumors for AG-120 was very similar, but that read through to solid tumor data at this point was premature.”
The analyst continued, “Agios expects updated data for AG-120 in heme malignancies by mid-2015, where we believe response rates and especially duration of response will be key. A robust duration of response would signal higher potential to meaningfully extend survival in our view, and would serve as a positive catalyst for the stock. To date, clinical data demonstrate an ORR of 50% in 14 IDH1m leukemia patients, with an impressive 29% CR, 14% CRi/CRp, which we find very positive for an oral drug since most patients in this disease state are heavily pretreated and elderly.”
The reason to own this fine co.--
Canaccord Pounds The Table On Agios Pharmaceuticals Following Fourth Quarter Update
February 17, 2015 11:54 AM EDT by Ben Mahaney, Editor in Exclusively Published • Healthcare • Insights
Canaccord Genuity analyst John Newman was out pounding the table on Agios Pharmaceuticals (NASDAQ:AGIO) Tuesday, reiterating a Buy rating and a price target of $163, following the company’s fourth-quarter results and update on its pipeline.
Newman wrote, “We expect data in solid tumors by 2H15 at a major medical conference, a key catalyst for the stock. We expect positive data due to the fact that IDH1 mutations